Helix BioPharma Corp. Board Changes

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors.

The Board has accepted the resignation of Dr. Marek Orlowski as a director of the Company. In his place, the Board is pleased to announce the appointment of Mr. Artur Gabor to the Board. Mr. Gabor has extensive experience in merger and acquisitions, corporate finance and restructuring.